← Back to Clinical Trials
Recruiting NCT07136844

NCT07136844 Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07136844
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Liege
Condition Neuromuscular Diseases
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2024-03-29
Primary Completion 2029-12

Trial Parameters

Condition Neuromuscular Diseases
Sponsor Centre Hospitalier Universitaire de Liege
Study Type INTERVENTIONAL
Phase N/A
Enrollment 300
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-03-29
Completion 2029-12
Interventions
SydeDynamometric measurements of muscle strengthThe 6-minute walk test (6MWT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Conducted at the Centre de Référence Liégeois des Maladies Neuromusculaires in Liège, Belgium, the study will enroll 300 ambulant patients, including individuals with neuromuscular disorders and obesity. Using the Syde® wearable device, the study aims to continuously monitor motor function in real-life settings over a period of up to two years. The primary objective is to evaluate the utility of digital mobility outcomes, such as the 95th centile of stride velocity (SV95C), as reliable and objective endpoints for future clinical trials.

Eligibility Criteria

Inclusion Criteria: * Ambulant patients (i.e. able to walk 10 meters without assistance) * Confirmed diagnosis by the investigator based on current gold standard in his/her disease (genetic testing, clinical criteria, etc.) * Myotonic dystrophy type 1 (DM1) and Charcot-Marie-Tooth (CMT) patients should present sensitive of motor signs on physical examination. * Myasthenic patients should be seropositive, and Myasthenia Gravis Foundation of America (MGFA) class II to IV. * Patient with morbid obesity (Body Mass Index\> or = 35 at inclusion visit). * Signed informed consent form by patient him/herself and patient willing and able to comply with all study procedures. Exclusion Criteria: * Non-ambulant patients * Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed * Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs * A concomitant chroni

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology